Current Studies
Clinical Studies
Trailblazer Alzheimer's Study
The Trailblazer Alzheimer’s Study involves people who have normal memory, thinking, mood and behavior patterns. Participants are randomly assigned to one of two groups. They receive either the investigational drug or a placebo. Those who receive placebo may have the option to receive the investigational drug at a later time.
You may be able to take part in this study if you:
- Be 55 to 80 years of age
- Have normal memory, thinking, mood and behavior patterns
- Have a reliable study partner* who knows you and is willing to attend appointments with you throughout the study
- Meet additional study requirements
AVP Alzheimer’s Study
The ASPECT Study will look at an investigational medication for people with Alzheimer’s Disease. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer’s Dementia.
The ASPECT Study might be right for you if you:
- Be between the ages of 50 and 90
- Have a diagnosis of probable Alzheimer’s disease
- Have moderate-to-severe agitation that interferes with daily life
- Have a caregiver who spends a minimum of 2 hours per day, 4 days a week with them and is willing and able to comply with all study procedures
AZT-001 Alzheimer’s Study
This clinical research trial is enrolling men and women who may have evidence of early stage Alzheimer’s disease. The clinical trial is evaluating whether a combined treatment slows down early stage Alzheimer’s disease.
Qualified participants must:
- Be 55 to 79 years old
- Have mild memory impairment
- Have a spouse, close person or relative who spends a lot of time with the participant to accompany the participant at study visits
- Be in good general health
Embark Alzheimer’s Study
Subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies.
Qualified participants must:
- Was participating in an aducanumab clinical study at the time of the announcement of early termination
- Has one care partner who has adequate contact with the participant as to be able to provide accurate information about the participant’s cognitive and functional abilities
- Must be in good health
BAN2401-201OLE Alzheimer’s Study
This medical study is for people who are experiencing increasing problems with their memory that may be early symptoms of Alzheimer’s disease. This study will evaluate the effectiveness of an investigational product (study drug). You must have been enrolled in the double-blind study.
Qualified participants must:
- Was participating in the double-blind clinical study
- Has one care partner who has adequate contact with the participant as to be able to provide accurate information about the participant’s cognitive and functional abilities
- Must be in good health
Clarity Alzheimer’s Study
18-Month study with an open-label extension phase to confirm safety and efficacy of an investigational drug in subjects with early Alzheimer’s Disease.
Qualified participants must:
- Male or female subjects aged ≥50 and ≤90 years
- Have an identified study partner for the duration of the study and who spends at least 8 hours per week with the you
- Must be in good health
Graduate Alzheimer’s Study
Study With an Open-Label Extension Phase to Confirm Safety and Efficacy in subjects with early (prodromal to mild) Alzheimer’s.
Qualified participants must:
- Age 50-90 years old at screening
- A study partner who has frequent and sufficient contact (e.g., 5 times per week or approximately 10 ours per week)
- Must be in good health
MIRROR Gout Study
A study testing efficacy and safety of two drugs to increase response rates in patients with Uncontrolled Gout.
Qualified participants must:
- Adult men or women ≥18 years of age
- Have uncontrolled gout
Alithios Multiple Sclerosis Study
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of an investigational drug in subjects with relapsing multiple sclerosis.
Qualified participants must:
- Had participated in the double-blind clinical study
Exchange Multiple Sclerosis Study
An open label study exploring safety and tolerability of conversion to Oral Siponimod in patients with relapsing multiple sclerosis.
Qualified participants must:
- Male/female aged 18 to 65 at screening
- Have advancing RMS
- Having been continuously treated with beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide for at least 3 months at the time of consent OR having had last natalizumab dose at least 4 weeks before screening OR last ocrelizumab dose 14 weeks prior to screening
Select Cardiac Study
Effects of Semaglutide on cardiovascular outcomes in people with overweight or obesity.
Qualified participants must:
- Male/Female age 45 and up at time of consent
- Documented myocardial infarction, stroke or PAD
- BMI of 27 or greater
SK Life Science 17/21 Seizure Study
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension.
Qualified participants must:
- Male/Female age 18 to 70 years old
- A diagnosis of partial epilepsy according to the International League Against Epilepsy’s
- Classification of Epileptic Seizures
PrecMed Parkinson’s Study
The purpose of this medical study is to collect biological samples from subjects with Parkinson’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Parkinson’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Parkinson’s disease. Your samples will be kept indefinitely by the sponsor.
PrecMed Alzheimer’s Study
The purpose of this medical study is to collect biological samples from subjects with Alzheimer’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Alzheimer’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Alzheimer’s disease. Your samples will be kept indefinitely by the sponsor.
PrecMed Multiple Sclerosis Study
The purpose of this medical study is to collect biological samples from subjects with Multiple Sclerosis. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Multiple Sclerosis or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Multiple Sclerosis. Your samples will be kept indefinitely by the sponsor.
Traumatic Brain Injury
The purpose of this medical study is to evaluate an investigational drug to see if it could potentially help behavioral changes resulting from a Traumatic Brain Injury (TBI). Many people are diagnosed with a TBI every year, including a significant number of veterans. This injury could lead to a number of behavioral changes, including outbursts and acts of aggression. This could be behavioral changes associated with the traumatic brain injury from at least 6 months ago. This clinical study is seeking these participants to research this investigational drug. Participants must have a study partner who interacts with them regularly and can attend all in-clinic study visits. There are no FDA-approved medications specifically for behavioral symptoms resulting from a TBI.